Despite the absence of detectable targeted mutations in the EGFR kinase domain in both GEP-NETs and lung carcinoids, preclinical data from a cancer cell series of LNETs suggested that the combination of Erlotinib and Everolimus may have synergistic effects on the inhibition of the EGFR/AKT/mTOR axis. This evidence concerns the gene EGFR and lung carcinoid tumor.